Seagen, Merck's Padcev-Keytruda combo snags FDA accelerated approval for bladder cancer
Seagen’s Padcev and Merck’s Keytruda have been cleared by the FDA as a combo for first-line treatment of bladder cancer, potentially pushing Padcev into a multibillion-dollar market just as Pfizer prepares to consummate its $43 billion buyout of Seagen.
The FDA handed out the accelerated approval based on positive data from a multi-cohort study with Padcev (enfortumab vedotin) and Keytruda (pembrolizumab) in patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing chemotherapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.